Thoracic intervention and surgery to cure lung: an overview of stereotactic ablative radiotherapy in early and oligometastatic lung cancer
|
|
- Audrey Smith
- 5 years ago
- Views:
Transcription
1 Series Journal of the Royal Society of Medicine; 0(0) 1 7 DOI: / Thoracic intervention and surgery to cure lung: an overview of stereotactic ablative radiotherapy in early and oligometastatic lung cancer BSH Chia 1, D Landau 2, G Hanna 3 and J Conibear 4 1 Division of Radiation Oncology, National Cancer Centre Singapore, Singapore , Singapore 2 Department of Clinical Oncology, Guy s and St Thomas Hospital, London SE1 7EH, UK 3 Department of Clinical Oncology, Belfast City Hospital, Belfast BT9 7AB, UK 4 Department of Clinical Oncology, St. Bartholomew s Hospital, London EC1A 7BE, UK Corresponding author: BSH Chia. brendan.chia.s.h@singhealth.com.sg This article is one of a series on thoracic surgery. Introduction Stereotactic ablative radiotherapy Stereotactic ablative radiotherapy is defined as the use of external beam radiotherapy to deliver high doses of radiation (usually 6 Gy) very precisely to an extracranial target within the body, as a single or small number of fractions. High doses of radiation result in larger biological effective doses and have unique radiobiological processes, 1 resulting in dramatic tumour responses thus termed ablative. It was first developed in 1951 to treat brain tumours which were surgically inoperable. Over the next half century, significant improvements in radiotherapy techniques led to improvements in the precision and safety of radiotherapy thus allowing delivery of higher doses of ablative radiation to target lesions. This technique is also known as stereotactic body radiotherapy for extracranial lesions and stereotactic radiosurgery for intracranial lesions. Technicalities of stereotactic ablative radiotherapy To achieve ablative doses, the machines employed to deliver stereotactic ablative radiotherapy treatments utilise multiple, finely collimated radiation beams or arcs to produce highly reproducible and conformal treatment plans. Radiotherapy plans will require tight margins and steep dose gradients between tumours and surrounding normal tissues. Fourdimensional computed tomography simulation scans that acquire images throughout the respiratory cycle are often used to take into account organ movements due to free breathing. An important aspect of the treatment is precise patient positioning and immobilisation using body fix or similar devices to ensure set-up accuracy. Accurate targeting of lesions using image guidance or fiducial matching is also important. During the treatment of lung and liver sites which are susceptible to intrafraction respiratory movements, multiple methods can be employed to reduce movement uncertainties such as respiratory gating, abdominal compression, deep inspiration breath-hold techniques or real-time tracking. Given that high doses per fraction and tight margins are used, it is important to minimise any mistakes as this would result in significant target miss or serious overdoses, thus rigorous quality assurance programmes 2 must be in place and strictly maintained. Stereotactic ablative radiotherapy in early nonsmall cell lung cancer Historically, patients with inoperable early stage nonsmall cell lung cancer would be treated with conventionally fractionated radiotherapy (using <2 3 Gy per fraction over a period of 3 6 weeks). The results were often lower than surgical outcomes with fiveyear cancer-specific survival rates of between 12% and 39%. 3 Methods to improve on radiotherapy outcomes were needed. Some of the earliest phase 1 study data in lung stereotactic body radiotherapy were published in 2003 by Timmerman et al. The same group subsequently reported in phase 2 trials excellent threeyear local control rates of 90.6%. 4 This landmark trial now forms the basis for international lung stereotactic ablative radiotherapy practice. Stereotactic ablative radiotherapy in early stage (T1-2aN0) inoperable non-small cell lung cancer has been established in several international guidelines! The Royal Society of Medicine 2018 Reprints and permissions: sagepub.co.uk/journalspermissions.nav
2 2 Journal of the Royal Society of Medicine 0(0) (Figure 1). Many prospective trials using different dose regimens have published excellent 2 3-year local tumour control and 1 3-year overall survival rates: 84 98% and 43 72%, respectively. 5 These studies also reported very low rates of severe, grade 3 4 toxicities. The optimal dose and schedule for stereotactic ablative radiotherapy varies between centres and physicians. This is largely determined by tumour location, tumour size and normal organ constraints. In primary non-small cell lung cancer, ablative doses with a biological effective dose of >100 Gy at isocentre have been shown to be a significant factor in local control and survival outcome in primary lung cancer. 6 The role of stereotactic ablative radiotherapy in surgical candidates is less certain. Comparative data analysis for both stereotactic ablative radiotherapy and surgery was also conducted using the SEER database. 7 Analyses have shown that stereotactic ablative radiotherapy was associated with a lower risk of early mortality but long-term survival was inferior compared to the surgical group. This might, however, be partly explained by an elderly, less fit cohort in the inoperable stereotactic ablative radiotherapy group. Recently, there has also been a pooled analysis 8 of two randomised trials called ROSEL (The Dutch Radiosurgery or Surgery for Operable Early stage non-small cell Lung cancer study) and STARS (Stereotactic Radiotherapy versus Surgery). Both trials set out to compare stereotactic ablative radiotherapy to surgery but were terminated early due to poor accrual. The pooled three-year overall survival was superior in the stereotactic ablative radiotherapy arm 95% versus 79% than in the surgical arm (hazard ratio 0.14 [95% confidence interval ]). In the stereotactic ablative radiotherapy arm, three patients (10%) experienced a grade 3 toxicity and the three-year recurrence-free survival was 86%. The results are in keeping with other published institutional data, but due to the small numbers it is not feasible to claim superiority of one treatment option over another. There are at least four ongoing prospective randomised trials that will provide additional guidance for surgical patients. In the UK, the SABRTooth trial has closed for accrual and results are awaited. Other internationally run trials are the joint Lung Cancer Trialist s Coalition STABLE-MATES trial, POSTLIV from China and the Veterans Affairs lung cancer surgery or stereotactic radiotherapy VALOR study. In the meantime, management decisions in operable patients should be discussed as a multidisciplinary team with clear presentation of available evidence Figure 1. Case of stereotactic ablative radiotherapy to primary non-small cell lung cancer central lung tumour. (a) Pretreatment positron emission tomography-computed tomography imaging with solitary right upper lobe tumour; (b) stereotactic ablative radiotherapy planned to 54 Gy in three fractions, showing multiple beam arrangement, targeted at lesion and (c) three-month post-treatment computed tomography showed near complete resolution of lesion.
3 Chia and Conibear 3 during physician patient consultations. Nevertheless, stereotactic ablative radiotherapy remains a good option in high-risk surgical candidates. Stereotactic ablative radiotherapy in oligometastatic non-small cell lung cancer The oligometastatic paradigm in lung cancer has gained increasing acceptance. This select group of patients typically has up to three isolated metastases although some definitions allow as many as five. Traditionally, palliative systemic therapy remains the standard of care for stage IV non-small cell lung cancer patients. However, there is growing evidence both retrospectively and prospectively that offering select patients with few metastases a more aggressive approach to management can result in good outcomes. This is reflected by updates in international guidelines to now recommend more aggressive therapies in a select group of patients with oligometastatic disease. In non-small cell lung cancer, recently implemented Eighth American Joint Committee on Cancer (AJCC) TNM staging system has redefined its classification for M1 stage disease by splitting solitary and multiple metastases on the basis that survival rates between these groups have been shown to be significantly different. 9 In a pooled analysis 10 of 2531 patients presenting with metastatic disease for treatment on consecutive SWOG protocols, those with a single metastatic lesion had significantly longer survival (8.7 months) compared to those with multiple metastases in a single organ (6.2 months) or those with multiple organs (5.1 months). The incidence of oligometastatic disease is relatively common with a rate as high as 50% in stage IV non-small cell lung cancer patients. This reported incidence is likely to have been influenced using improved imaging techniques which have higher sensitivity for detecting more subtle sites of metastatic spread, e.g. positron emission tomography imaging and brain magnetic resonance imaging. Notably, some oligometastatic patients do not progress to widespread disease on follow-up. 11 It would thus be reasonable to hypothesise that locally aggressive treatments could potentially cure these patients or provide improved long-term disease control. Figure 2. Case of stereotactic ablative radiotherapy to adrenal gland oligometastases. (a) Pretreatment positron emission tomography-computed tomography imaging with solitary right adrenal metastases. (b) A fiducial seed (blue arrow) was inserted for radiotherapy treatment targeting. (c) Stereotactic ablative radiotherapy planned. Concentric coloured lines show steep dose fall off. (d) Ten-month post-stereotactic ablative radiotherapy positron emission tomography-computed tomography shows complete resolution of adrenal metastases.
4 4 Journal of the Royal Society of Medicine 0(0) Figure 3. Case of stereotactic ablative radiotherapy to solitary non-small cell lung cancer brain metastases. (a) Pretreatment T1- weighted magnetic resonance imagingþcontrast showing solitary right temporal brain lesion; (b) stereotactic ablative radiotherapy planned to 24 Gy in three fractions; (c) four-month post-stereotactic ablative radiotherapy magnetic resonance imaging showed good response and (d) unfortunately, 18-month follow-up magnetic resonance imaging showed disease progression of the treated lesion. Traditionally this has often been done with surgery. However, due to existing co-morbidities or inoperability of the site of disease, this is often not an option. Non-invasive ablative methods such as stereotactic ablative radiotherapy, chemical ablation, radiofrequency ablation, cryoablation and highintensity focused ultrasound become more attractive options (Figure 2). With the depth of experience, evidence and availability of intracranial stereotactic radiosurgery and primary lung stereotactic ablative radiotherapy treatments, stereotactic ablative radiotherapy in metastatic disease is quickly becoming a more established option and there is now a growing pool of literature supporting its use. Several retrospective and a few single-arm prospective trials specific to lung cancer patients have reported their own experience in treating these select patients who have a limited number of metastatic lesions with stereotactic ablative radiotherapy. In general, these are single-arm studies that have reported improvements in the patient s long-term disease-free survival and overall survival comparative to historical results. Ashworth et al. 12 reported a systematic review which included 757 patients internationally with treated non-small cell lung cancer oligometastases. All patients had the primary lung cancer treated aggressively as well as 1 5 oligometastases. A total of 37.7% of patients were treated with radiotherapy to their oligometastases. The pooled median overall survival was 26 months with a favourable overall survival of 29.4% at five years. Median progression-free survival was 11 months but at five years 13.1% of patients remained progression-free, suggesting benefit of local ablative technique. On multivariate analysis, nodal disease and synchronous metastases and non-
5 Chia and Conibear 5 adenocarcinoma histology had worse overall survival. Two randomised trials have been reported so far. The first by Gomez et al. 13 was a multi-centre phase II trial which randomised non-small cell lung cancer patients with 3 metastases who did not progress after induction systemic treatment to either local consolidative therapy (surgery or radiotherapy to all metastases, with or without systemic therapy) or to systemic therapy alone. The study was closed early after 49 patients were enrolled as interim analysis found the median progression-free survival in the consolidative therapy arm to be 14.4 months compared to 3.9 months in the standard arm. Median overall survival was not reached. The second and recently published study was by Texas Southwestern Medical Centre. 14 They enrolled 29 patients with similar enrolment criteria, but their study design allowed for 6 sites of metastatic disease. The study was stopped early as interim analysis showed a significant progression-free survival advantage in the stereotactic ablative radiotherapy arm (9.7 versus 3.5 months). Stereotactic ablative radiotherapy resulted in no in-field failure versus seven in the maintenance only arm. No additional toxic effect was noted in the stereotactic ablative radiotherapy arm and median overall surival was also not reached. In oligometastatic lesions, a dose control relationship is also observed 15 although the optimal dose required has not yet been defined. The trials reported to date are heterogenous and have treated patients with metastatic lesions at many different organ sites with different doses. Thus, it is reasonable to give as high a biological effective dose as possible providing it does not compromise the radiation tolerance of local normal tissues. Several studies have also looked at the role of ablative treatment to specific sites of metastatic spread in non-small cell lung cancer. The brain is a common site of spread with significant risk of morbidity; good control is thus essential. Stereotactic radiosurgery to brain oligometastases The role of aggressive management of non-small cell lung cancer with limited brain metastases was established by Patchell et al. 16 In it, patients who had surgery in addition to whole brain radiotherapy had better local control (52% versus 20%) and overall survival (40 versus 15 weeks). Much of the evidence for stereotactic radiosurgery comes from its use in conjunction with whole brain radiotherapy. The RTOG 9508 trial 17 compared whole brain radiotherapy alone to whole brain radiotherapy with stereotactic radiosurgery boost to patients with oligometastatic brain lesions. Stereotactic radiosurgery boost allowed improved control. Importantly, there was an overall survival advantage in patients with better prognosis as well as an improvement in functional preservation. Other trials comparing the role of adjunct whole brain radiotherapy to stereotactic radiosurgery alone 18 showed that the addition of whole brain radiotherapy did not result in an overall survival advantage despite better local control. This could potentially spare patients the neurotoxicities of whole brain radiotherapy while improving the quality of life (Figure 3). There is also evidence for the use of stereotactic radiosurgery to the surgical cavity postoperatively 19 to improve local control (72% versus 43% at 12 months) with no adverse events reported. Stereotactic radiosurgery can be given in 1 5 fractions depending on size of tumour, location to critical structures (e.g. brain stem, optic chiasm) as well as prior brain radiation. The criteria for most trials limit stereotactic radiosurgery to four brain lesions each <3 cm; however, some centres treat even greater number of lesions. A common complication of stereotactic radiosurgery is tumour swelling that can result in compressive symptoms and delayed brain radiation necrosis in about 10% of cases, approximately half of which may be asymptomatic. Although there are no comparative trials for stereotactic radiosurgery versus surgery in brain oligometastases, the evidence suggests that stereotactic radiosurgery is a very suitable option, especially in those patients with small inoperable lesions and treatment options should be individualised. Conclusion and future directions The optimal management of early and oligometastatic non-small cell lung cancer is likely to change over time as more clinical trial data become available. For inoperable early stage non-small cell lung cancer, stereotactic ablative radiotherapy is already an important non-invasive method of achieving good local control and survival outcomes with low rates of treatment toxicity. Trials looking at optimising the dose and fractionation schedules of central (RTOG 0813) and peripheral (NCT , Roswell Park Cancer Institute) tumours are underway and will help guide physicians better. Continued improvements in radiation technology and planning systems are likely to increase our ability to deliver higher doses of radiation to tumours with improved accuracy and reduced normal tissue toxicity. Particle beam therapy has a different physical beam profile to that of photons and could
6 6 Journal of the Royal Society of Medicine 0(0) allow significant improvement in dose distributions and potential treatment outcomes, although head-to-head trials would need to be conducted to validate this. For operable, early stage non-small cell lung cancer patients, stereotactic ablative radiotherapy remains an important treatment modality particularly for those patients who are considered high-risk operative candidates. Future randomised trial results will hopefully help guide treatment decisions for these patients better. In oligometastatic disease, novel biomarkers are currently being investigated to help define patients who are truly oligometastatic from those that are polymetastatic. Recently, microrna 20 expression profiles have demonstrated promising results and have been found to have prognostic value. These studies though are limited by small sample sizes and therefore further prospective studies are needed to help develop and validate this method to help guide future patient selection. Due to the lack of randomised prospective data, level 1 evidence to support the use of stereotactic ablative radiotherapy in oligometastatic non-small cell lung cancer patients is lacking. The timing and appropriate integration of stereotactic ablative radiotherapy into the treatment regimen of patients is still uncertain. Several ongoing trials will hopefully help clarify this matter. The NCT , Wake Forest University and ATOM (NCT ) trials are looking at the role of consolidation radiotherapy after systemic treatment and epidermal growth factor receptor targeted therapies, respectively. In the UK, the SARON trial (NCT ) is a multicentre randomised phase III trial of stereotactic ablative radiotherapy with standard chemotherapy versus standard chemotherapy alone in synchronous oligometastatic non-small cell lung cancer. The optimal dose fractionation when treating multiple oligometastases in various organ sites is still unknown and most published literature includes stereotactic ablative radiotherapy for solitary lesions. The NRG BR001 (NCT ) trial will attempt to clarify the safety and tolerability of stereotactic ablative radiotherapy to multiple metastases. In the evolving field of metastatic non-small cell lung cancer treatments, targeted molecular agents such as epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors are commonly used. Interaction with these agents is uncertain. NCT , which is a multicentre randomised phase 2 trial comparing stereotactic ablative radiotherapy with erlotinib to erlotinib alone, will attempt to provide a measure of the benefit of stereotactic ablative radiotherapy as local ablative therapy of oligometastatic disease in oncogene-driven nonsmall cell lung cancer. Of late, immunotherapy has been a hot topic in the management of non-small cell lung cancer. There is growing interest in combining stereotactic ablative radiotherapy, which is thought to be immunogenic, with novel immune checkpoint inhibitors such as anti-ctla-4 and anti-pd-1 or PD-L1 antibodies to potentiate the antitumour immune response. Preclinical in vivo mouse models and case reports of combined treatments have suggested potential synergistic effects and are now being investigated in prospective trials such as the Dutch PEMBRO-RT study (NCT ). While we await further prospective data, it is important to consider the evidence so far; stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer is promising but its current use should be weighed against the risks involved, be it a multidisciplinary team-based decision and if possible, conducted within the context of a well-designed prospective randomised trial. Stereotactic ablative radiotherapy for early non-small cell lung cancer, on the other hand, is well established and remains an important curative treatment option, particularly for those patients unsuitable for radical surgery. Declarations Competing Interests: None declared. Funding: None declared. Ethical approval: Not applicable Guarantor: BSHC. Contributorship: (I) Conception and design: all authors; (II) administrative support: none; (III) provision of study materials or patients: none; (IV) collection and assembly of data: all authors; (V) data analysis and interpretation: all authors; (VI) manuscript writing: all authors; (VII) final approval of manuscript: all authors. Acknowledgements: None Provenance: Not commissioned; peer-reviewed by Tom Treasure. References 1. Brown JM, Carlson DJ and Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 R s involved? Int J Radiat Oncol Biol Phys 2014; 88: Solberg TD, Balter JM, Benedict SH, Fraass BA, Kavanagh B, Miyamoto C, et al. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: executive summary. Pract Radiat Oncol 2012; 2: Rowell NP and Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev 2001; 2: CD
7 Chia and Conibear 7 4. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: Ricardi U, Badellino S and Filippi AR. Stereotactic body radiotherapy for early stage lung cancer: history and updated role. Lung Cancer 2015; 90: Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2: S94 S Yu JB, Soulos PR, Cramer LD, Decker RH, Kim AW and Gross CP. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Cancer 2015; 121: Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: Albain KS, Crowley JJ, LeBlanc M and Livingston RB. Survival determinants in extensive-stage nonsmall-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhisle MJ, Stares M and Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 2009; 48: Ashworth AB, Senas S, Palma DA, Riguet M, Ahn YC, Ricardi U, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 2014; 15: Gomez DR, Blumenschein Jr GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016; 17: Iyengar P, Wardark Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018; 4: e McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B, et al. Observation of a dosecontrol relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009; 73: Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: Soon YY, Tham IW, Lim KH, Koh WY and Lu JJ. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev 2014; CD Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN and Weichselbaum RR. Towards a molecular basis of oligometastatic disease: potential role of micro-rnas. Clin Exp Metastasis 2014; 31:
Radiotherapy What are our options and what is on the horizon. Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology
Radiotherapy What are our options and what is on the horizon Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology Outline Advances in radiotherapy technique Oligo - disease Advancements
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationPerspectives on oligometastasis: challenges and opportunities
Editorial Perspectives on oligometastasis: challenges and opportunities Jana Heitmann, Matthias Guckenberger Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland Correspondence
More informationPalliative radiotherapy in lung cancer
New concepts and insights regarding the role of radiation therapy in metastatic disease Umberto Ricardi University of Turin Department of Oncology Radiation Oncology Palliative radiotherapy in lung cancer
More informationTherapy of Non-Operable early stage NSCLC
SBRT Stage I NSCLC Therapy of Non-Operable early stage NSCLC Dr. Adnan Al-Hebshi MD, FRCR(UK), FRCP(C), ABR King Faisal Specialist Hospital & Research Centre This is our territory Early Stages NSCLC Surgical
More informationSABR. Outline. Stereotactic Radiosurgery. Stereotactic Radiosurgery. Stereotactic Ablative Radiotherapy
CAGPO Conference October 25, 2014 Outline Stereotactic Radiation for Lung Cancer and Oligometastatic Disease What Every GPO should know Dr. David Palma, MD, MSc, PhD Radiation Oncologist, London Health
More information4.x Oligometastases: evidence for dose-fractionation
4.x Oligometastases: evidence for dose-fractionation Background 4.x.1. The oligometastatic state can be defined as 1-3 isolated metastatic sites, typically occurring more than six months after successful
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationClinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology
Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationTania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015
Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015 Most common brain tumor, affecting 8.5-15% of cancer patients. Treatment options: Whole brain radiation
More informationStereotactic ablative radiotherapy in early NSCLC and metastases
Stereotactic ablative radiotherapy in early NSCLC and metastases Scheduled: 0810-0830 hrs, 10 March 2012 Professor Suresh Senan Department of Radiation Oncology SABR in stage I NSCLC A major treatment
More informationStereotactic body radiation therapy versus surgery for patients with stage I non-small cell lung cancer
Review Article Page 1 of 9 Stereotactic body radiation therapy versus surgery for patients with stage I non-small cell lung cancer Tomoki Kimura Department of Radiation Oncology, Hiroshima University Hospital,
More information20. Background. Oligometastases. Oligometastases: bone (including spine) and lymph nodes
125 20. Oligometastases Background The oligometastatic state can be defined as 1 3 isolated metastatic sites, typically occurring more than six months after successful treatment of primary disease. 1 In
More informationHot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
More informationNew Radiation Treatment Modalities in the Treatment of Lung Cancer
New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions
More informationRadioterapia nella malattia oligometastatica. Fiorenza De Rose, M.D., Radiotherapy and Radiosurgery Dep. Humanitas Clinical and Research Hospital
Radioterapia nella malattia oligometastatica Fiorenza De Rose, M.D., Radiotherapy and Radiosurgery Dep. Humanitas Clinical and Research Hospital OUTLINE Definition of oligometastatic state Local ablative
More informationFROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017
FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE Geoffrey S. Ibbott, Ph.D. June 20, 2017 1 DISCLOSURES My institution holds Strategic Partnership Research Agreements with Varian, Elekta, and Philips
More informationClinical Study Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence
Pulmonary Medicine Volume 2012, Article ID 369820, 5 pages doi:10.1155/2012/369820 Clinical Study Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationEditorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD
Accepted Manuscript Editorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD PII: S0022-5223(18)33135-0 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.036
More information4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla
4D Radiotherapy in early ca Lung Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla Presentation focus on ---- Limitation of Conventional RT Why Interest in early lung cancer
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationAccepted Manuscript. Keeping Surgery Relevant in Oligometastatic Non-Small Cell Lung Cancer. Jessica S. Donington, MD, MSCR
Accepted Manuscript Keeping Surgery Relevant in Oligometastatic Non-Small Cell Lung Cancer Jessica S. Donington, MD, MSCR PII: S0022-5223(18)32903-9 DOI: https://doi.org/10.1016/j.jtcvs.2018.10.124 Reference:
More informationStereotactic ablative body radiotherapy for renal cancer
1 EVIDENCE SUMMARY REPORT Stereotactic ablative body radiotherapy for renal cancer Questions to be addressed 1. What is the clinical effectiveness of stereotactic ablative body radiotherapy for inoperable
More informationRadiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem
Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationTecniche Radioterapiche U. Ricardi
Tecniche Radioterapiche U. Ricardi UNIVERSITA DEGLI STUDI DI TORINO Should we always rely on stage? T4N0M0 Stage IIIB T2N3M0 Early stage NSCLC The treatment of choice for early-stage NSCLC is anatomic
More informationThe role of Radiation Oncologist: Hi-tech treatments for liver metastases
The role of Radiation Oncologist: Hi-tech treatments for liver metastases Icro Meattini, MD Radiotherapy-Oncology Unit AOU Careggi Hospital Florence University, Italy Liver Metastases - Background The
More informationClinical Commissioning Policy: The use of Stereotactic Ablative Radiotherapy (SABR) in the treatment of oligometastatic disease
Clinical Commissioning Policy: The use of Stereotactic Ablative Radiotherapy (SABR) in the treatment of oligometastatic disease Reference: NHS England: 16032/P 2 NHS England INFORMATION READER BOX Directorate
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationRole of SBRT in the management of lung and liver metastases. Ronan TANGUY, M.D. Radiation Oncologist
Role of SBRT in the management of lung and liver metastases Ronan TANGUY, M.D. Radiation Oncologist Oligometastatic RCC mrcc: Lung, Bone, Liver, Brain (Schlesinger-Raab, EJC2008) Targeted therapies Objective
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationClinical Commissioning Policy: Stereotactic Body Radiotherapy / Stereotactic Ablative Radiotherapy. December Reference : NHSCB/B1a
Clinical Commissioning Policy: Stereotactic Body Radiotherapy / Stereotactic Ablative Radiotherapy December 2012 Reference : NHSCB/B1a NHS Commissioning Board Clinical Commissioning Policy: Stereotactic
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationOligometastatic Disease
Oligometastatic Disease Fact or Fantasy? Jennifer R Bellon MD, FASTRO Dana-Farber Cancer Institute Harvard Medical School Alexander V Louie MD PhD, FRCPC London Health Sciences Center Western University
More informationRadiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer
Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer Poster No.: C-0654 Congress: ECR 2011 Type: Scientific Paper Authors:
More informationHong Kong Hospital Authority Convention 2018
Hong Kong Hospital Authority Convention 2018 Stereotactic Radiosurgery in Brain Metastases - Development of the New Treatment Paradigm in HA, Patients Profiles and Their Clinical Outcomes 8 May 2018 Dr
More information56 th Annual Meeting American Society for Radiation Oncology. Advances in Lung Caner News Briefing
56 th Annual Meeting American Society for Radiation Oncology Advances in Lung Caner News Briefing Moderator: Benjamin Movsas, MD, FASTRO Tuesday, Sept. 16, 2014 7 a.m. (PT) Long-term Results of RTOG 0236:
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationSUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT
SUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT Cheng-Ta Hsieh, 1 Cheng-Fu Chang, 1 Ming-Ying Liu, 1 Li-Ping Chang, 2 Dueng-Yuan Hueng, 3 Steven D. Chang, 4 and Da-Tong Ju 1
More informationAdvances in Radiation Therapy
Advances in Radiation Therapy 2017 Recent Advances in Oncology Michelle Alonso-Basanta, MD PhD Helene Blum Assistant Professor Associate Chief of Clinical Operations Director of Quality Assurance Chief,
More informationNRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
More informationClinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate
Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationSBRT in early stage NSCLC
SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques
More informationAdvaMed Medtech Value Assessment Framework in Practice
AdvaMed Medtech Value Assessment Framework in Practice Application of the Medtech Value Assessment Framework to Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Value Framework Overview
More informationFuture of Radiation Therapy
Future of Radiation Therapy JP Morgan Healthcare Conference January 12, 2016 Deepak Khuntia, MD, VP of Medical Affairs Patrick Kupelian, MD, VP of Clinical Affairs Cancer as a cause of death CANCER TREATMENT
More informationOn the use of 4DCT derived composite CT images in treatment planning of SBRT for lung tumors
On the use of 4DCT derived composite CT images in treatment planning of SBRT for lung tumors Zhe (Jay) Chen, Ph.D. Department of Therapeutic Radiology Yale University School of Medicine and Yale-New Haven
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationIGRT Protocol Design and Informed Margins. Conflict of Interest. Outline 7/7/2017. DJ Vile, PhD. I have no conflict of interest to disclose
IGRT Protocol Design and Informed Margins DJ Vile, PhD Conflict of Interest I have no conflict of interest to disclose Outline Overview and definitions Quantification of motion Influences on margin selection
More informationHigh-precision Radiotherapy
High-precision Radiotherapy a report by Professor Cai Grau and Dr Morten Hoyer Department of Oncology, Aarhus University Hospital, Denmark DOI: 10.17925/EOH.2005.0.0.40 Professor Cai Grau Dr Morten Hoyer
More informationTREATMENT DELIVERY AND CLINICAL EVIDENCE FOR THE TREATMENT OF OLIGOMETASTASIS
TREATMENT DELIVERY AND CLINICAL EVIDENCE FOR THE TREATMENT OF OLIGOMETASTASIS Dr Gerry Hanna Clinical Senior Lecturer in Radiation Oncology Centre for Cancer Research and Cell Biology Queens University
More informationLong-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
Fleckenstein et al. BMC Cancer (2016) 16:348 DOI 10.1186/s12885-016-2379-x RESEARCH ARTICLE Open Access Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell
More informationImplementing New Technologies for Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Implementing New Technologies for Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Implementation of radiosurgery and SBRT requires a fundamentally sound approach Errors don t blur out
More informationStereotactic Ablative Radiotherapy for Prostate Cancer
Stereotactic Ablative Radiotherapy for Prostate Cancer Laurie Cuttino, MD Associate Professor of Radiation Oncology VCU Massey Cancer Center Director of Radiation Oncology Sarah Cannon Cancer Center at
More informationStereotactic radiotherapy
Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH
More informationLinac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR
Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR PhD, FAAPM, FACR, FASTRO Department of Radiation Oncology Indiana University School of Medicine Indianapolis, IN, USA Indra J. Das,
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 Interventional radiology and stereotactic radiotherapy Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
More informationStereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery
Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery Matthew Hartwig, M.D. Duke Cancer Institute Case Presentation I: Patient ER 74 y/o male with A1A
More informationProtocol of Radiotherapy for Small Cell Lung Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationResponse Evaluation after Stereotactic Ablative Radiotherapy for Lung Cancer
Original Article PROGRESS in MEDICAL PHYSICS Vol. 26, No. 4, December, 2015 http://dx.doi.org/10.14316/pmp.2015.26.4.229 Response Evaluation after Stereotactic Ablative Radiotherapy for Lung Cancer Ji
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationRadiotherapy in feline and canine head and neck cancer
Bettina Kandel Like surgery radiotherapy is usually a localized type of treatment. Today it is more readily available for the treatment of cancer in companion animals and many clients are well informed
More informationRelevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationReference: NHS England B01X26
Clinical Commissioning Policy Proposition: The use of Stereotactic Ablative Radiotherapy (SABR) as a treatment option for patients with Hepatocellular carcinoma or Cholangiocarcinoma Reference: NHS England
More informationSubject: Image-Guided Radiation Therapy
04-77260-19 Original Effective Date: 02/15/10 Reviewed: 01/25/18 Revised: 01/01/19 Subject: Image-Guided Radiation Therapy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationRADIOTHERAPY- CURRENT SITUATION AND FUTURE TRENDS
HOSPITAL OF LITHUANIAN UNIVERSITY OF HEALTH SCIENCES KAUNO KLINIKOS RADIOTHERAPY- CURRENT SITUATION AND FUTURE TRENDS Prof. Elona Juozaitytė Perspectives of Czech- Lithuanian Research Partnerships About
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationFlattening Filter Free beam
Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationChapter 1 Introduction and outline of the thesis
Chapter 1 Introduction and outline of the thesis Introduction This thesis is focused on (1) the assessment and implementation of advanced radiotherapy technologies and treatment techniques, and (2) high-precision
More informationReference: NHS England: 16022/P
Clinical Commissioning Policy: The use of Stereotactic Ablative Radiotherapy (SABR) as a treatment option for patients with Hepatocellular carcinoma or Cholangiocarcinoma Reference: NHS England: 16022/P
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationPractical implementation of MR-guided RT: pancreatic SBRT as an example site
Practical implementation of MR-guided RT: pancreatic SBRT as an example site Anna Bruynzeel, MD PhD Dept. of Radiation Oncology VU University medical center Amsterdam, The Netherlands VU University Medical
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationSBRT for lung metastases: Case report
SBRT for lung metastases: Case report Guillermo de Velasco MD, PhD University Hospital 12 de Octubre @H12O_GUCancer @g_develasco Case report 71 years old man Smoker DM 2005 Right radical nephrectomy Histology:
More informationDisclosure for Dr. Gomez
Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized,
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationShyam B. Paryani M.D., M.S., M.H.A & Nitesh N. Paryani, M.D. May 1 st, th Annual Cardiovascular & Medicine Symposium St. Augustine, Florida
Shyam B. Paryani M.D., M.S., M.H.A & Nitesh N. Paryani, M.D. May 1 st, 2015 16 th Annual Cardiovascular & Medicine Symposium St. Augustine, Florida Outline Terminology & Background A brief historical overview
More informationUse of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation.
Radiation Therapy Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation. One person in three will develop some form of cancer in their lifetime.
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationSTAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY?
STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY? MICHAEL LANUTI, MD American Association of Thoracic Surgeons Minneapolis, MN 2013 STAGE I INOPERABLE NSCLC RADIOFREQUENCY
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationPlace de la radiothérapie dans les CBPC métastatiques
Place de la radiothérapie dans les CBPC métastatiques Cecile Le Péchoux, 12 ème Biennale Monégasque de Cancérologie, 2016 IOT Institut d Oncologie Thoracique CBPC metastatique Rapid doubling time, early
More informationUPDATE ON RADIOTHERAPY
1 Miriam Kleiter UPDATE ON RADIOTHERAPY Department for Companion Animals and Horses, Plattform Radiooncology and Nuclear Medicine, University of Veterinary Medicine Vienna Introduction Radiotherapy has
More information